Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arbutus Biopharma Cp (ABUS)

Arbutus Biopharma Cp (ABUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 327,719
  • Shares Outstanding, K 96,388
  • Annual Sales, $ 6,910 K
  • Annual Income, $ -63,750 K
  • 60-Month Beta 2.93
  • Price/Sales 45.73
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ABUS with:

Options Overview

Details
  • Implied Volatility 112.11%
  • Historical Volatility 58.41%
  • IV Percentile 12%
  • IV Rank 7.01%
  • IV High 787.99% on 07/08/20
  • IV Low 61.18% on 05/13/21
  • Put/Call Vol Ratio 0.41
  • Today's Volume 82
  • Volume Avg (30-Day) 1,633
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 43,002
  • Open Int (30-Day) 38,476

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.22
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.34
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.57 +26.46%
on 05/17/21
3.49 -6.88%
on 06/09/21
+0.63 (+24.05%)
since 05/14/21
3-Month
2.43 +33.74%
on 05/13/21
4.07 -20.15%
on 03/16/21
-0.53 (-14.02%)
since 03/15/21
52-Week
1.71 +90.06%
on 07/14/20
9.02 -63.97%
on 07/24/20
+1.41 (+76.63%)
since 06/15/20

Most Recent Stories

More News
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

Conference Call and Webcast to discuss the new data being presented at EASL scheduled for 8:00 AM ET, Monday, June 28, 2021

ABUS : 3.25 (-4.41%)
Arbutus to Participate in Upcoming Investor Conferences

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies...

ABUS : 3.25 (-4.41%)
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 3.25 (-4.41%)
Arbutus: Q1 Earnings Snapshot

WARMINSTER, Pa. (AP) _ Arbutus Biopharma Corp. (ABUS) on Wednesday reported a loss of $16.4 million in its first quarter.

ABUS : 3.25 (-4.41%)
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV)...

ABUS : 3.25 (-4.41%)
Arbutus Biopharma Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Arbutus Biopharma Corp. (NASDAQ:ABUS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 8:45 AM...

ABUS : 3.25 (-4.41%)
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO

Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO

EPRX.TO : 4.01 (-3.37%)
ABUS : 3.25 (-4.41%)
JNJ : 165.22 (-0.09%)
Thinking about buying stock in ADMA Biologics, Deutsche Bank, Boxlight Corp, Tellurian, or Arbutus Biopharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADMA, DB, BOXL, TELL, and ABUS.

ABUS : 3.25 (-4.41%)
ADMA : 1.7900 (-2.72%)
BOXL : 2.71 (-1.45%)
TELL : 4.29 (-2.05%)
DB : 14.06 (+0.50%)
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies...

ABUS : 3.25 (-4.41%)
Stocks Pause as Big Tech Bonanza Begins

Stocks Pause as Big Tech Bonanza Begins

RAIL : 5.57 (-7.63%)
CAAP : 5.22 (-0.76%)
RYAM : 7.70 (+1.05%)
MAN : 122.66 (-0.36%)
AA : 35.12 (-4.95%)
ASIX : 29.54 (+0.41%)
FHB : 28.73 (+1.02%)
SAVA : 73.15 (-3.48%)
NVAX : 191.97 (-7.58%)
GCI : 5.55 (-2.80%)
ARLO : 6.82 (-1.02%)
USFD : 38.91 (-1.02%)
SQ : 228.29 (-1.15%)
VFF : 10.47 (-1.13%)
NOW : 506.96 (-0.47%)
ABUS : 3.25 (-4.41%)
MRNA : 203.45 (-1.91%)
NTLA : 86.20 (-2.05%)
CSCO : 53.88 (-0.54%)
WMMVY : 32.3900 (-0.83%)
WLK : 98.63 (-0.90%)
ARMK : 37.74 (+0.27%)
TAL : 28.43 (-4.66%)
GOOG : 2,520.04 (-0.28%)
MSFT : 258.92 (-0.37%)
AAPL : 130.04 (-0.34%)
FB : 336.50 (-0.08%)
QCOM : 136.75 (-0.41%)
BA : 246.95 (+0.74%)
SHOP : 1,326.01 (+1.48%)
F : 14.91 (+0.27%)
EBAY : 65.71 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 3.59
2nd Resistance Point 3.51
1st Resistance Point 3.45
Last Price 3.25
1st Support Level 3.32
2nd Support Level 3.25
3rd Support Level 3.19

See More

52-Week High 9.02
Fibonacci 61.8% 6.23
Fibonacci 50% 5.37
Fibonacci 38.2% 4.50
Last Price 3.25
52-Week Low 1.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar